Bayer Shares Climb On Birth-control Confirmation Test

Shares of Bayer AG [s:bayn:de] climbed 3% Wednesday after the medical-products giant announced the U.S. Food and Drug Administration approved the use of transvaginal ultrasound to confirm the company's Essure birth-control method is properly placed. Previously, women using Essure had to get an X-ray of the reproductive areas after they were filled with contrasting dye. Essure involves the placement of soft, flexible barriers into the fallopian tubes to prevent pregnancy. Shares were up $3.70 to $129.15 in recent action.